导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.97% | 40/147 |
| 近一周 | -2.31% | 21/153 |
| 近一月 | -1.37% | 42/153 |
| 近一季 | -0.23% | 33/153 |
| 近半年 | -1.91% | 46/149 |
| 近一年 | -5.68% | 25/144 |
| 近两年 | 43.46% | 40/119 |
| 近三年 | 41.30% | 15/89 |
| 成立以来 | 39.30% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.69% 113/360 |
-6.63% 243/366 |
- - |
- - |
| 2025 | 28.54% 44/358 |
14.73% 99/340 |
4.03% 194/348 |
12.34% 124/354 |
-4.14% 205/358 |
| 2024 | 20.21% 116/329 |
-2.85% 202/280 |
8.15% 48/310 |
20.42% 79/318 |
-4.99% 237/329 |
| 2023 | -12.57% 174/275 |
2.13% 94/205 |
-6.72% 180/230 |
-6.69% 188/262 |
-1.64% 175/276 |
| 2022 | -15.58% 71/201 |
-6.61% 45/153 |
-0.71% 65/164 |
-20.34% 122/189 |
14.30% 58/202 |
| 2021 | -12.75% 70/150 |
3.49% 99/312 |
2.51% 176/328 |
-13.79% 255/358 |
-4.60% 75/151 |
| 2020 | -0.62% 55/103 |
-14.89% 192/280 |
3.92% 236/295 |
-2.66% 235/299 |
15.44% 51/305 |
| 2019 | 10.40% 68/88 |
11.53% 92/258 |
-0.22% 182/268 |
-8.42% 240/253 |
8.33% 98/266 |
| 2018 | -13.28% 54/79 |
- - |
- - |
- - |
-6.94% 83/241 |
| 2017 | 36.55% 3/69 |
- - |
- - |
- - |
- - |
| 2016 | 3.49% 34/59 |
- - |
- - |
- - |
- - |
| 2015 | -4.81% 28/49 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 广发中证香港创新药ETF(QDII) | 1.2744 | 27.49% |
| 广发道琼斯石油指数人民币A | 3.2498 | 26.68% |
| 广发道琼斯石油指数人民币C | 3.1927 | 26.58% |
| 广发道琼斯石油指数(QDII-LOF)人民币E | 3.2003 | 26.55% |
| 广发中证香港创新药ETF发起式联接(QDII)C | 1.3286 | 26.01% |
| 富国标普石油天然气勘探及生产精选行业ETF(QDII) | 1.4105 | 25.68% |
| 汇添富恒生生物科技ETF(QDII) | 1.1055 | 25.31% |
| 南方恒生生物科技ETF(QDII) | 1.1206 | 25.14% |
| 华宝标普油气上游股票美元A | 0.1538 | 24.94% |
| 广发中证香港创新药ETF发起式联接(QDII)A | 1.3401 | 24.24% |
| 华夏恒生ETF联接现汇 VS. 建信富时100指数(QDII)人民币A(539003) |